While it's been believed for some time that people with diabetes seem to have a higher incidence of osteoporosis, a new study indicates a connection between the widely used Type 2 diabetes drug Rosiglitazone (brand name Avandia) and loss of bone. The research was published in Nature Medicine. The theory is that the medication inhibits the patient's osteoblasts, the cells responsible for building bone. Physician's don't recommend discontuing the dedication because of these concerns (never do so without talking to your doctor) but extra attention to preserve you bone health may be warranted. If you or someone you know is taking this medicine, a discussion with a physician about osteoporosis may be in order.
Published On: December 09, 2007